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Germline mutations in the RAS/ERK signaling
pathway underlie several related developmental
disorders collectively termed neuro-cardio-facial-
cutaneous (NCFC) syndromes. NCFC patients mani-
fest varying degrees of cognitive impairment, but the
developmental basis of their brain abnormalities
remains largely unknown. Neurofibromatosis type 1
(NF1), an NCFC syndrome, is caused by loss-of-func-
tion heterozygous mutations in the NF1 gene, which
encodes neurofibromin, a RAS GTPase-activating
protein. Here, we show that biallelic Nf1 inactivation
promotes Erk-dependent, ectopic Olig2 expression
specifically in transit-amplifying progenitors, leading
to increased gliogenesis at the expense of neurogen-
esis in neonatal and adult subventricular zone (SVZ).
Nf1-deficient brains exhibit enlarged corpus cal-
losum, a structural defect linked to severe learning
deficits in NF1 patients. Strikingly, these NF1-associ-
ated developmental defects are rescued by transient
treatment with anMEK/ERK inhibitor during neonatal
stages. This study reveals a critical role for Nf1 in
maintaining postnatal SVZ-derived neurogenesis
and identifies a potential therapeutic window for
treating NF1-associated brain abnormalities.INTRODUCTION
RAS genes are the key intracellular mediators that transmit
signals from cell surface receptors to downstream effector path-
ways, regulating cell proliferation, survival, and differentiation
(Bos, 1989; Downward, 2003). One of the major RAS-regulated
downstream effector pathways is mediated by the extracellular816 Cell 150, 816–830, August 17, 2012 ª2012 Elsevier Inc.signal-regulated kinase (ERK) subfamily of mitogen-activated
protein kinases (MAPKs), which is comprised of a kinase
cascade of RAF, MEK, and ERK (Rubinfeld and Seger, 2005).
Somatic-activating mutations in RAS and RAF are among the
most frequent gain-of-function alterations in human cancer,
highlighting a critical role for the RAS-RAF-MEK-ERK pathway
in human oncogenesis (Bos, 1989; Downward, 2003). Recent
studies have revealed that germline mutations in the compo-
nents of the RAS/ERK pathway are associated with a group of
clinically related developmental disorders, including Noonan,
LEOPARD, cardio-facio-cutaneous (CFC), Costello, Legius,
and neurofibromatosis type 1 (NF1) syndromes, which has
been collectively referred to as neuro-cardio-facial-cutaneous
(NCFC) syndromes or ‘‘RASopathies’’ (Bentires-Alj et al., 2006;
Samuels et al., 2009; Schubbert et al., 2007; Tidyman and
Rauen, 2009). One of the most important unknown aspects of
NCFC syndromes is themechanism(s) underlying the substantial
neurocognitive burden of these diseases. Particularly, the devel-
opmental basis of brain abnormalities in NCFC syndrome
patients remains largely unknown.
Most NCFC syndromes are caused by dominant-activating
mutations in the RAS/ERK signaling pathway in the germline.
However, NF1 is arguably an exception because it is caused
by germline recessive loss-of-function mutations in one of the
two NF1 alleles (NF1+/) (Bentires-Alj et al., 2006; Samuels
et al., 2009; Schubbert et al., 2007; Tidyman and Rauen, 2009).
The NF1 gene encodes a RAS GTPase-activating protein
(GAP) neurofibromin, which promotes the conversion of an
active RAS-GTP bound form to an inactive RAS-GDP form,
thus functioning as a negative regulator of RAS/ERK signaling
pathway (Cichowski and Jacks, 2001). Between 30% and 70%
of NF1 patients have learning disabilities—the most significant
cause of lifetime morbidity associated with these patients
(Hyman et al., 2005). Recent studies using genetically engi-
neered mouse (GEM) models have shown that heterozygous
Nf1 inactivation (Nf1+/) causes behavioral abnormalities with
similarities to learning disabilities in NF1 patients (Cui et al.,
2008). However, Nf1+/ mice exhibit no evidence of structural
brain defects such as enlarged corpus callosum (CC), which
has been recently associated with severe learning disabilities
observed in a subpopulation of NF1 patients (Moore et al.,
2000; Pride et al., 2010). The CC is comprised of neuronal fibers
that connect the two brain hemispheres, as well as the two
primary glial cell types: oligodendrocytes that form myelin of
axons, and astrocytes that provide trophic and functional
support for neurons (Rowitch and Kriegstein, 2010). The clinical
observations that only a subpopulation of NF1 patients exhibits
an enlarged CC argue that monoallelic NF1 inactivation
(NF1+/) is not sufficient to induce these structural brain defects.
It has recently been shown that some NF1-related nontumor
manifestations such as skin hyperpigmentation and bone abnor-
malities result from biallelic NF1 inactivation (NF1/) caused by
‘‘second-hit’’ mutations in the remaining wild-type NF1 alleles of
somatic cells (De Schepper et al., 2008; Stevenson et al., 2006).
Accordingly, we hypothesize that the structural brain defects
such as the enlarged CC observed in a subset of NF1 patients
could be caused by biallelic NF1 inactivation in developing
neural stem cells. Compared to differentiated cells, stem cells
have greater potentials for self-renewal, and consequently, one
or few NF1/ stem cells could produce a greater number of
progeny that manifest clinical symptoms (Kriegstein and
Alvarez-Buylla, 2009). Therefore, NF1-associated structural
brain abnormalities may provide a unique opportunity to define
the timing and cellular targets of somatic ‘‘second-hit’’ NF1
mutations and, more importantly, the phenotypic consequences
of hyperactive RAS/ERK signaling in developing stem cell
lineages underlying these brain abnormalities.
Most glial cells in the CC arise from neural progenitor cells that
are specified by a basic-helix-loop-helix transcription factor,
Olig2, in the subventricular zone (SVZ) of the lateral ventricle
during perinatal stages (Marshall et al., 2005; Richardson et al.,
2006; Rowitch and Kriegstein, 2010). Olig2 is both sufficient
and necessary for specifying SVZ progenitors to adopt glial
fates. Olig2 promotes their differentiation to both oligodendro-
cytes and astrocytes during neonatal stages, but only to oligo-
dendrocytes in adulthood (Cai et al., 2007; Hack et al., 2005;
Marshall et al., 2005; Menn et al., 2006). Loss of Olig2 leads
to a nearly complete absence of glial cells including both oligo-
dendrocytes and astrocytes in the postnatal CC (Cai et al.,
2007). During mouse embryonic development, the SVZ initially
is comprised of neuron-restricted progenitors, also known as
transit-amplifying progenitors or intermediate progenitor cells
(TAP/IPCs), which express Tbr2 and give rise to excitatory
projection neurons in the cerebral cortex from embryonic day
14.5 to 17.5 (E14.5–E17.5) (Molyneaux et al., 2007). When neuro-
genesis ceases at E17.5 in the cerebral cortex, gliogenesis
ensues and persists into postnatal stages. However, one multi-
potent neural stem cell population with neurogenic activity in
the SVZ persists into adulthood, and this region forms the largest
germinal zone in the adult brain (Ihrie and Alvarez-Buylla, 2011;
Kriegstein and Alvarez-Buylla, 2009). The SVZ stem cell lineage
is organized in a hierarchy: type B cells (SVZ-B) are multipotent
stem cells expressing glial fibrillary acidic protein (GFAP),
which give rise to type C cells (SVZ-C) that are multipotent
TAP/IPCs. The SVZ-C TAP/IPCs subsequently differentiate intotwo lineage-restricted progenitors: (1) neuron-restricted type A
neuroblasts (SVZ-A) that migrate along rostral migratory stream
(RMS) and differentiate into inhibitory neurons in the olfactory
bulb (OB), and (2) glia-restricted progenitors that migrate and
differentiate into glial cells populating the overlying CC and
surrounding brain parenchyma (Ihrie and Alvarez-Buylla, 2011;
Kriegstein and Alvarez-Buylla, 2009). The cellular output of
neonatal and adult SVZ stem and progenitor cells is dramatically
different. Although neonatal SVZ cells simultaneously produce
a large number of neurons and glial cells in the OB and CC,
respectively, adult SVZ cells predominately generate neurons
in the OB (>90%) (Hack et al., 2005; Marshall et al., 2005;
Menn et al., 2006). The mechanism(s) by which postnatal
SVZ stem and progenitor cells suppress Olig2 expression and
maintain high levels of neurogenesis in an otherwise gliogenic
environment of the postnatal brain is not well understood.
In this study we developed GEM models that allow spatially
and temporarily controlled inactivation of Nf1, and demonstrate
the critical role(s) of the Nf1-regulated Erk pathway in embryonic,
neonatal, and adult SVZ stem and progenitor cell functions.
Furthermore, we define a therapeutic window that may allow
treatment of NF1-associated structural brain defects.
RESULTS
Biallelic Inactivation of Nf1 Leads to an Enlarged CC
To determine whether biallelic inactivation of Nf1 leads to
structural brain defects observed in a subpopulation of NF1
patients, we targeted an Nf1 conditional mutation into radial
glia by using a Cre transgenic strain under the control of the
human GFAP promoter (hGFAP-cre) (Zhu et al., 2001; Zhuo
et al., 2001). During embryonic development, radial glia are the
primary neural stem cell populations, which give rise to neurons,
glia, and adult neural stem cells in the SVZ (Kriegstein and Al-
varez-Buylla, 2009). The onset of hGFAP-cre expression occurs
in 95% of E12/E13 radial glia in the forebrain, thus inactivating
Nf1 in both embryonic and adult neural stem cells as well as their
differentiated progeny (Malatesta et al., 2003). Nf1 conditional
knockout (CKO) mice with the genotypes of hGFAP-cre+;
Nf1flox/flox or hGFAP-cre+;Nf1flox/ were referred to as
Nf1hGFAPCKO (Nf1/) because both genotypes showed similar
phenotypes analyzed in this study. Germline (Nf1+/) or condi-
tional (hGFAP-cre+;Nf1flox/+) heterozygous mice exhibited no
overt structural or cellular defects in the brain, indicating that
monoallelic Nf1 inactivation is not sufficient to induce the struc-
tural brain defects observed in human NF1 patients. In contrast,
Nf1 conditional biallelic inactivation caused a 10%–15%
increase in the size of cerebral cortical surface area, amanifesta-
tion often observed in human NF1 patients (Figures 1A and 1B).
We next measured and compared the size of the CC at three
different sagittal positions along the midline to lateral hemi-
sphere of control and Nf1hGFAPCKO brains at 2 months of age
(Figures 1C and 1C0). At all three positions that are directly asso-
ciated with the SVZ of the lateral ventricle (P1–P3), Nf1 inactiva-
tion caused a significant increase in the thickness of the CC
(Figures 1D and 1E; see Figures S1A–S1C available online). Of
note the CC from the midline section, which is not directly asso-
ciated with the SVZ, showed no increase in thickness (Figures 1ECell 150, 816–830, August 17, 2012 ª2012 Elsevier Inc. 817
Figure 1. Nf1-Deficient Adult Brain Exhibits Enlarged CC and Reduced OB
(A, A0, and B) Whole-mount images and size quantification of control (CTR) and Nf1hGFAPCKO brains and OB. MUT, mutant.
(C and C0) Schematic demonstration of different histological planes used for analysis, the SVZ/RMS/CC/OB system, and the orientation of brains analyzed
(A, anterior; P, posterior; D, dorsal; V, ventral).
(D) Sagittal sections from control and Nf1hGFAPCKO brains at 2 months were analyzed at P2 position, stained with hematoxylin and eosin (H&E) and imaged at
three increasingly higher magnifications. The cells that form chain-like structures (arrowheads) were exclusively observed in the mutant CC.
(E) The thickness of the control and mutant CC was quantified.
(F and G) Coronal sections from control and mutant brains were stained with NF200/Olig2 and MBP/Olig2. Lower panels in (F) are the high-magnification view
of delineated CC areas in the upper panels.
(H and I) Ultrathin sections were subjected to EM analysis from dorsal to ventral CC. Representative EM images from two histological planes are shown in (H) and
(I). Asterisks (*) indicate degenerating tissues only observed in the mutant CC. Ctx, cerebral cortex.
(J an K) Two sets of EM images covering the entire thickness of the CC at two parallel positions (column 1 and column 2) and at comparable histological planes
were analyzed. The total number of axons (J) and cell bodies (K) in each column from three controls and three mutants was quantified.
(L) Total cell density in the CC was quantified and compared at P1, P2, P3, and M positions based on H&E-stained sections.
(M–O) Control and mutant CCs were stained for GFAP/Olig2, and their density was quantified in (N). The number of cells expressing both GFAP and Olig2
(arrows, M) was significantly increased in mutant CC (O). Dashed lines delineate the border of the CC.
All the quantification data are presented as mean ± SEM. LV and *, lateral ventricle. Scale bars, 50 mm except for (H) and (I) at 2 mm.
See also Figure S1.and S1D). These observations demonstrate that biallelic, but not
heterozygous, inactivation ofNf1 leads to an enlargedCC specif-
ically associated with the SVZ.
To determine the mechanism underlying the enlarged CC, we
first examined whether there was an increase in the number of818 Cell 150, 816–830, August 17, 2012 ª2012 Elsevier Inc.neurons in the cerebral cortex that project their axons to the
CC (Molyneaux et al., 2007; Richards et al., 2004). The number
of NeuN+ cortical neurons, Ctip2+ deep-, or Cux1+ upper-layer
neurons was not significantly different between control and
Nf1hGFAPCKO brains (Figures S1E–S1E00). Second, we examined
whether there was an increase in the number of axons in the
Nf1hGFAPCKO CC. From the coronal sections, we confirmed
that the enlargement of the CC occurred specifically in the areas
directly associated with the SVZ, but not in the midline (Figures
1F, S1F, and S1F0). Compared to controls, neurofilament 200
(NF200, an axonal marker) staining revealed a more diffused
and reduced expression pattern in the Nf1hGFAPCKO CC (Fig-
ure 1F). At the ultrastructural level, only amarginal, but not statis-
tically significant, increase in the number of axons was observed
in the Nf1hGFAPCKO CC compared to that of controls (Figures
1H–1J, S1G, and S1H). In contrast, the number of cell bodies
was significantly increased on the same sections analyzed by
electron microscopy (EM) (Figure 1K). Consistently, a robust
increase in both the absolute number and density of cells in
the SVZ-associated CC of Nf1hGFAPCKO brains was observed
on thicker sections compared to controls (Figures 1D, 1L, and
S1A–S1C). The increased number in GFAP+ and Olig2+ glial
lineage cells appeared to be the major contributing factor for
the increased cellular density (Figures 1M–1O). Together, these
results suggest that an increase in the number of glial cells, but
not the number of axons or cortical neurons, is mainly respon-
sible for the enlarged SVZ-associated CC in Nf1hGFAPCKO
brains. In support of this conclusion, no CC alteration was
observed in neuron-specific Nf1 CKO mice driven by Synapsin
I-cre (Figure S1F00) (Zhu et al., 2001). It is worth noting that
despite a relatively normal appearance of myelination (Fig-
ure 1G), varying degrees of tissue degeneration were observed
in the CC of Nf1hGFAPCKO brains (Figure 1I).
Nf1-Deficient Adult Brain Exhibits an Enlarged SVZ with
Increased Glial Differentiation
Despite a disproportionately enlarged SVZ-associated CC,
one discernible structural difference between control and
Nf1hGFAPCKO forebrains was the significantly reduced size of
the OB, the destination of SVZ-derived neurons (Figures 1A
and 1A0). The contrasting size alterations observed in the two
brain structures related to SVZ-derived gliogenesis and neuro-
genesis raise the possibility that these phenotypes could result
from functional impairments of Nf1-deficient SVZ stem and
progenitor cells. We therefore analyzed the SVZ from these
mice at the same three positions used for the CC studies. At
each of these three positions, Nf1hGFAPCKO SVZ exhibited a 2-
to 3-fold size increase compared to controls (Figures 2Aa–
2Ab00, 2B, and S2A–S2C). To investigate the relative contribution
of SVZ cells to its increased size, we determined the number of
individual SVZ cell populations by using lineage markers.
Compared to controls, the percentage of SVZ cells expressing
glial lineage markers including GFAP, Olig2, and NG2 was mark-
edly increased with a concomitant reduction in Doublecortin
(Dcx)-expressing neuroblasts in the Nf1hGFAPCKO SVZ (Figures
2Ac–2Ah0 and 2C). Furthermore, a greater number of GFAP+ cells
accumulated and formed a less-cellular area in the anterior-
dorsal part of the Nf1hGFAPCKO SVZ, which was not identified
in the control SVZ (dotted areas in Figures 2Ab00, 2Ad, 2Ad0,
and S2A). These GFAP+ cells exhibited the features of differenti-
ated astrocytes including the presence of multiple long cellular
processes, and a lack of expression of stem/progenitor marker
Nestin or Ki67 (Figures 2Ad and S3A). Together, these resultsdemonstrate that Nf1 inactivation leads to an enlarged SVZ
with aberrant accumulation of differentiated glial cells.
Nf1 Inactivation Impairs the Balance of Glial versus
Neuronal Output in the Adult SVZ
Abnormally increased numbers of glial lineage cells observed in
the Nf1hGFAPCKO SVZ/CC system could result from an increase
in proliferation or a reduction in apoptosis of SVZ stem and/or
progenitor cells, as expected from loss of Nf1 tumor suppressor
function. To investigate this possibility, we performed an in vivo
bromodeoxyuridine (BrdU)-labeling assay and in vitro neuro-
sphere assays (Figure S3). These studies demonstrate that alter-
ations in proliferation or apoptosis in adultNf1hGFAPCKO SVZ are
unlikely to contribute to increased glial lineage cells in the
enlarged SVZ. We next investigated whether Nf1 inactivation
altered glial versus neuronal fate specification by examining
Olig2 expression in the SVZ stem cell lineages. No Olig2 expres-
sion was observed in GFAP+ SVZ-B stem cells or lineage-
restricted Dcx+ SVZ-A neuroblasts in the adult control or
Nf1hGFAPCKOSVZ (FigureS2E; data not shown). Previous studies
showed that Ascl1+ progenitor cells in the embryonic and
neonatal SVZ selectively express the Dlx1/2 homeodomain tran-
scription factors or Olig2, directing neural stem and progenitor
cells to adopt neuronal or glial fates, respectively (Marshall
et al., 2005; Parras et al., 2004; Petryniak et al., 2007). Consistent
with the previous studies indicating that glial output of adult SVZ
stem cells is minor (5%–10%) (Hack et al., 2005; Menn et al.,
2006), approximately 9% of multipotent Ascl1+ TAP/IPCs
expressed Olig2 in the control adult SVZ (Figures 2D–2F). Strik-
ingly, nearly half of Ascl1+ TAP/IPCs expressed Olig2 in the
Nf1hGFAPCKO SVZ (48.3%; Figures 2D–2F). These results are
most consistent with a model wherein Nf1 inactivation promotes
ectopic expression of Olig2 specifically in SVZ-C TAP/IPCs that
normally undergoneuronal differentiation, leading toan increased
output of glial cells at the expense of neuronal differentiation. This
hypothesis is supported by the observation that Nf1 inactivation
leads to an enlarged CCwith a concomitant reduction in OB size.
To further test this hypothesis, we performed a long-term
BrdU pulse-chase experiment on 2-month-old control and
Nf1hGFAPCKO mice. Thirty days after BrdU pulses, we analyzed
the number and identity of newly generated SVZ-derived
BrdU+ cells in the SVZ/RMS/OB/CC system. Compared to
control brains, there was more than a 2-fold increase of BrdU+
cells in the SVZ/RMS/CC and surrounding areas of
Nf1hGFAPCKO brains (Figures 3A and 3B). All of the BrdU+ cells
in the CC of both control and Nf1hGFAPCKO brains expressed
Olig2, but not other lineage markers including GFAP, Pax6, or
Dcx (Figure 3C; data not shown). The rate of proliferation or
apoptosis of Olig2+ cells was not significantly different between
the control andmutant CC (Figures 3D and 3D0; data not shown).
These results indicate that the increase of glial cells in the
Nf1hGFAPCKO CC is unlikely contributed by locally increased
proliferation or reduced apoptosis in the mutant CC. Strikingly,
we observed a 9-fold increase of BrdU+ cells in theNf1hGFAPCKO
RMS compared to controls (Figures 3E and 3F). Although a small
number of BrdU+ cells observed in the control RMS were Pax6-
or Dcx-expressing migrating neuroblasts, over half of the BrdU+
populations in the Nf1hGFAPCKO RMS expressed Olig2 or GFAPCell 150, 816–830, August 17, 2012 ª2012 Elsevier Inc. 819
Figure 2. Nf1hGFAPCKO SVZ Shows Increased Glial Differentiation and Ectopic Olig2 Expression in Ascl1+ TAP/IPCs
(A) Representative sections of the control andmutant SVZ at P2 position were stained with H&E and imaged at threemagnifications (a–b
00). The high-magnification
views of the boxed area in (a) and (b) are shown in (a0) and (a00) and (b0) and (b00), respectively. Adjacent sections were stained for Nestin/GFAP (c and d), Olig2/NG2
(e and f), and GFAP/Dcx (g and h). Arrows identify Olig2+/NG2+ cells, and arrowheads mark Olig2+/NG2 cells (e–f0).
(B) The number of cells per unit length of LV at P1–P3 was quantified.
(C) The percentage of SVZ cells expressing different lineage markers (Ac–Ah0) was quantified.
(D and E) Olig2/Dlx2/Ascl1 triple-immunofluorescence labeling was performed on sections from control and mutant brains. In the ventral (D) and dorsal (E) SVZa,
Olig2+/Dlx2+/Ascl1+ triple-positive cells (white) and Olig2+/Dlx2/Ascl1+ double-positive cells (pink) are marked by arrows and arrowheads, respectively.
(F) The percentage of Ascl1+ cells expressing Olig2 and/or Dlx2 was quantified and compared between the control and mutant SVZ.
All the quantification data are presented as mean ± SEM. LV and *, lateral ventricle. St, striatum. Scale bars, 50 mm.
See also Figures S2 and S3.(Figures 3E–3G). Consistently, a nearly 3-fold increase in Olig2-
and NG2-expressing cells was observed in the Nf1hGFAPCKO
RMS, some of which expressed myelin basic protein (MBP)
(Figures S4A–S4C). The abnormal myelination in the mutant
RMS may contribute to the progressive disruption of neuronal
migratory chain over time (Figure S4D). Consistently, Pax6+/
BrdU+-migrating neuroblasts were accumulated and signifi-
cantly increased in theNf1hGFAPCKORMS compared to controls
(Figures 3E and 3F). In contrast to a marked increase in gliogen-
esis in the CC and RMS, the number of BrdU+ cells in the OB of
Nf1hGFAPCKO mice was greatly reduced compared to controls
(Figure 3A). Most of the BrdU+ cells in the control OB were newly
generated NeuN+ neurons, which were reduced by 50% in the
mutant OB (Figures 3H and 3H0). No significant difference in
the BrdU+/NeuN nonneuronal populations was observed, indi-
cating that local gliogenesis in the OB was not affected by Nf1820 Cell 150, 816–830, August 17, 2012 ª2012 Elsevier Inc.inactivation. Taken together, these observations demonstrate
that Nf1 plays a critical role in regulating glial versus neuronal
output in the adult SVZ stem cell niche by suppressing Olig2
expression in Ascl1+ SVZ-C TAP/IPCs.
Acute Inactivation of Nf1 Is Sufficient to Induce
Glial/Neuronal Fate Switch in the Adult SVZ
To determine whether abnormal glial/neuronal fate specification
reflects an ongoing cell-autonomous requirement for Nf1
function in adult SVZ progenitors or abnormal SVZ niche
environment, we employed an inducible system in which Cre
recombinase (Nestin-creER) can be activated in Nestin-express-
ing cells by tamoxifen (TM) treatment (Figure S5) (Burns et al.,
2007). To target adult SVZ cells, we established a 5 day TM
induction protocol frompostnatal day 26 (P26) to P30 (Figure 4A).
TM-induced Nestin-creER -mediated recombination specifically
Figure 3. Nf1 Inactivation Leads to
Increased Gliogenesis in the CC at the
Expense of Neurogenesis in the OB
A BrdU pulse-chase assay from P60 to P90 was
performed to label newly differentiated neurons
and glia.
(A and B) Low-magnification view (A) and the
quantification of the overall distribution of BrdU+
cells in P90 control and mutant brains (B). Arrows
identify BrdU+ cells in the CC, and arrowheads
mark the abnormal increase of BrdU+ cells in the
mutant RMS. The dashed line marks the border of
the OB and the forebrain.
(C) Increased Olig2+/BrdU+ cells (arrows) were
observed in the mutant CC compared to controls.
(D and D0) A short-term BrdU proliferation assay
was performed on P60 mice.
(E) Thirty days after BrdU pulse, the identity of
BrdU+ cells in the RMS was revealed by triple or
double labeling of BrdU with Pax6/GFAP (a and b),
Dcx/GFAP (c and d), or Olig2 (e and f). Arrows and
arrowheads indicate BrdU double- and single-
labeling cells, respectively.
(F and G) The number and ratio of BrdU+ cells that
coexpressed Pax6, GFAP, or Olig2 in the control
and mutant RMS were quantified.
(H) Sections of the control and mutant OB were
stained for BrdU, NeuN, and DAPI. The number of
BrdU+/NeuN+ (arrows) and BrdU+/NeuN cells per
OB surface area was quantified in (H0).
All the quantification data are presented asmean ±
SEM. *, lateral ventricle. Scale bars, 50 mm.
See also Figure S4.targets neural stem and progenitor cells in the SVZ as well as
neuroblasts in the RMS, but not cells in the CC or OB of the adult
brain (Figure 4B). This genetic approach allowed us to perform
long-term lineage-tracing analysis for SVZ-derived glial cells in
the CC and neurons in the OB because no cells in these two
structures were directly targeted by this Nestin-creER transgene
(Figure 4O). We injected TM into control and Nf1NcreERCKOmice
from P26 to P30, and analyzed the distribution and identity of
Nestin-creER-targeted SVZ/RMS-derived cells 1 month later. At
P60, the number of control and Nf1-deficient SVZ cells, marked
by b-gal expression, was not significantly different betweenCell 150, 816–830TM-treated control and Nf1NcreERCKO
mice (Figures 4C and 4D). Moreover, the
percentage of proliferating BrdU+ cells
in the b-gal+ cell populations of the
control and Nf1NcreERCKO SVZ was also
comparable, confirming that Nf1 inacti-
vation confers no significant growth
advantage to adult SVZ cells (Figures 4E
and 4F). However, the percentage of
b-gal+ cells expressing Olig2 was greatly
increased, indicating that acute inacti-
vation of Nf1 in the normal SVZ niche is
sufficient to induce ectopic expression
of Olig2 in adult SVZ cells (Figures 4G
and 4H). Consistently, b-gal+ cells thatall expressed Olig2 were dramatically increased and often
formed clusters in the CC of TM-treated Nf1NcreERCKO brains
(Figures 4C, 4D, 4I, and 4J). Together, these results demonstrate
that acute Nf1 inactivation promotes ectopic Olig2 expression
in adult SVZ cells and, subsequently, enhances SVZ-derived
gliogenesis in the CC.
Consistent with the notion of the Nf1-deficiency-dependent
glial/neuronal fate switch, the number of b-gal+ cells in the
RMS was significantly reduced in TM-induced Nf1NcreERCKO
brains (Figure 4D). Moreover, a subpopulation of the b-gal+ cells
expressed Olig2 in the mutant RMS, whereas all the b-gal+ cells, August 17, 2012 ª2012 Elsevier Inc. 821
Figure 4. Acute Inactivation of Nf1 Induces a Glia/Neuron Fate Switch in the Adult SVZ
(A) The summary of the genotypes of inducible mouse models and the time frame of TM induction and analysis.
(B) Young adult mice were induced by TM from P26 to P30 and analyzed at P31. The cells undergoing Cre-mediated recombination revealed by X-gal staining
were restrictedly distributed in the SVZ and RMS.
(C–N) Control and mutant brains induced by TM from P26 to P30 were analyzed at P60. (C) X-gal staining of the SVZ/RMS/CC system shows the cluster of b-gal+
cells (dashed lines) exclusively identified in the mutant CC. Arrowheads identify individual b-gal+ cells in the CC. (D) The number of b-gal+ cells in the control
andmutant SVZ/RMS/CCwas quantified. (E and F) The proliferation rate of b-gal+ cellsmarked by BrdU stainingwas not significantly different between the control
and mutant SVZ. (G–L) The b-gal+ cells coexpressing Olig2 in the control and mutant SVZ (G and H), CC (I and J), and RMS (K and L) are identified by arrows and
quantified.Arrowheads label noncolocalizingcells. The inset in (K) shows thecoexpressionofb-gal andDcx in thecontrolRMS.Dashed linesdelineate theSVZand/
or RMS region. (M) TheOB fromTM-induced control andNf1NcreERCKObrainswas stainedwith X-gal and compared. The number of b-gal+ cellswasquantified (N).
(O) An illustration summarizes the cell lineages targeted by Nestin-creER and their respective derivatives.
All the quantification data are presented as mean ± SEM. LV, lateral ventricle. Scale bars, 50 mm.
See also Figure S5.in the control RMS were Dcx+/Olig2 neuroblasts (Figures 4K
and 4L). These results suggest that Nf1 inactivation not only
increases SVZ-derived gliogenesis in the CC but also alters the822 Cell 150, 816–830, August 17, 2012 ª2012 Elsevier Inc.migratory pattern of some glial progenitor cells that abnormally
enter into the RMS. Because it requires about 14 days for a neu-
roblast to complete its migration from the SVZ to OB (Ihrie and
Alvarez-Buylla, 2011), the b-gal+ neuroblasts observed in the
RMS 30 days after TM induction would be exclusively derived
from multipotent neural stem and progenitor cells in the SVZ
(Figure 4K). In contrast a considerable number of b-gal+ neurons
in the OB were derived from Nestin-creER-targeted neuroblasts
in the RMS. Thus, a 2-fold decrease in the number of SVZ-
derived neuroblasts in the mutant RMS opposed to a marginal
reduction in SVZ-derived neurogenesis in the mutant OB could
reflect the fact that Nf1 has a dispensable role in neuroblast
migration and differentiation (Figures 4M–4O). Collectively, these
observations demonstrate that acute inactivation of Nf1 confers
no proliferative advantage to adult SVZ cells but, instead, alters
glial/neuronal fate specification by promotingOlig2 expression in
adult SVZ progenitor cells in a cell-autonomous manner.
Nf1 Suppresses Olig2 Expression in Neonatal SVZ
Progenitor Cells
Despite an ongoing requirement for Nf1 function in regulating
fate specification of adult SVZ progenitor cells, acute inactivation
of Nf1 in adult SVZ cells did not produce any of the structural
defects (e.g., enlarged CC or SVZ) observed in Nf1hGFAPCKO
brains. We therefore sought to investigate the timing and mech-
anism(s), when and by which Nf1 inactivation leads to impaired
fate specification of SVZ cells and enlarged CC during develop-
ment. We measured the size and cell number of the anterior SVZ
(SVZa) and posterior SVZ (SVZp), and no significant difference
was identified between control and Nf1hGFAPCKO forebrains at
birth (Figures 5Aa, 5Aa0, S6A, and S6D). The overall rate of prolif-
eration or apoptosis in the SVZ was not significantly altered
(Figures S6B and S6C). Compared to controls, however, one
striking phenotype observed was a nearly 3-fold increase in
the number of cells that expressed Olig2 in the Nf1hGFAPCKO
SVZa (Figures 5Ab, 5Ab0, and 5B). No increase in the percentage
of Ki67+ proliferating cells in the Olig2+ lineage was observed,
indicating that Olig2+ cells were not hyperproliferative in the
Nf1hGFAPCKO SVZa (Figures 5C and 5D). Given no alteration in
proliferation or apoptosis observed in the Nf1hGFAPCKO SVZa,
we investigated the possibility of whether Nf1 inactivation
leads to ectopic Olig2 expression in SVZa stem and progenitor
cells in neonatal brains. Although the number of Ascl1+ cells
was comparable between control and Nf1hGFAPCKO SVZa
(p = 0.104), the percentage of Olig2-expressing cells in Ascl1+
populations (Olig2+/Ascl1+) was greatly increased from 16.7%
in controls to 38.7% in mutants (Figures 5E and 5F). Concomi-
tantly, the Dlx2+/Ascl1+ progenitor populations were reduced
from 82.5% to 65.3% (Figures 5E and 5F). Moreover, the
percentage of Ascl1+ cells that expressed both Olig2 and Dlx2
was increased from 5.5% to 11.8% (Figures 5Eb, 5Eb0, and
5F). These observations suggest that similar to its role in the
adult SVZ, Nf1 inactivation promotes ectopic Olig2 expression
in Ascl1+ SVZ progenitors in neonatal stages.
Unlike the SVZa, neural stem/progenitor cells and more differ-
entiated cells in the SVZp areas are spatially separated in the
VZ/SVZp and overlying intermediate zone (IZ), respectively (Fig-
ure 5G). In the Nf1hGFAPCKO VZ/SVZp, we observed a greater
than 2-fold increase in the number of Olig2+ cells, whereas the
number of Dlx2+ cells was not significantly changed (Figures
5G and 5H). Similar to the SVZa, the increased Olig2 expressionin the VZ/SVZp was also not caused by increased proliferation
(Figures S6E and S6F) but instead was caused by ectopic
Olig2 expression in Ascl1+ and Dlx2+ progenitors (Figures S6F,
S6I and, S6J). Of note, Olig2 expression was not expanded in
Pax6+ VZ and Tbr2+ SVZ progenitor cells (Figures S6G and
S6H). In the IZ the expression of Olig2 and Dlx2 is almost
mutually exclusive, suggesting that once cells become more
differentiated, they selectively express only one of these two
transcription factors. Strikingly, Nf1hGFAPCKO IZ cells exhibited
a substantial loss of Dlx2 expression with a concomitant
increase of Olig2-expressing cells (Figures 5G and 5H). This
observation suggests that ectopic Olig2 expression suppresses
Dlx2 expression as these cells become more differentiated and
migrate to the IZ, leading to overproduction of Olig2+ lineage
cells at the expense of the Dlx2+ lineages.
Nf1-Related Structural Brain Defects Are Established
during Neonatal Development
We observed no significant difference in the size of control and
Nf1hGFAPCKO brains including OB at P0.5 and P8 (Figures 6A–
6C). However, by P18 the size of the mutant OBwas significantly
reduced to a similar degree to that observed in the adult (Figures
6D and S8E). Notably, neuronal clusters, which could be readily
identified in the control OB, were largely absent in mutants (Fig-
ure 6E). These observations suggest that the glial/neuronal fate-
specification defect caused by Nf1 inactivation is largely estab-
lished during postnatal stages from P8 to P18. To test this, we
pulsed control and Nf1hGFAPCKO mice with BrdU at P8 and
analyzed the BrdU-treated mice at P18. SVZ-derived newborn
neurons labeled by BrdU and NeuN (BrdU+/NeuN+) were mark-
edly reduced in the Nf1hGFAPCKO OB compared to controls
(Figures 6E–6G). It is worth noting that the number of BrdU+ cells
coexpressing the neuronal lineage marker Pax6 was not signifi-
cantly different between the control and Nf1hGFAPCKO RMS
(Figures S7A and 7B). This observation suggests that, in contrast
to adulthood, the reduced neurogenesis in the neonatal mutant
OB is unlikely contributed by migratory defects in the RMS.
Compared to controls, the number of BrdU+ cells was increased
by more than 3-fold in the Nf1hGFAPCKO RMS and CC, where
most of the BrdU+ cells expressed glial markers, GFAP and
Olig2 (Figures 6H–6J and S7B–S7D). These observations
demonstrate that Nf1 inactivation leads to increased gliogenesis
at the expense of neurogenesis in the neonatal SVZ/RMS/OB/
CC system. Interestingly, the ratio of newly generated GFAP+/
BrdU+ astrocytes and Olig2+/BrdU+ oligodendrocytes was not
significantly different in the CC of control and Nf1hGFAPCKO
brains, indicating that Nf1 inactivation only promotes overpro-
duction of Olig2+ progenitors but does not alter the potential of
these Olig2+ progenitors to differentiate into astrocytes or oligo-
dendrocytes (Figure 6K) (Cai et al., 2007; Marshall et al., 2005).
It is worth noting that the size and cell number ofNf1hGFAPCKO
SVZ were already significantly increased at P8, and this was
accompanied by an increase in proliferation of GFAP+ stem cells
(Figures 6L–6N). Because Nf1 inactivation confers no growth
advantage to adult SVZ cells, this observation suggests that
Nf1 is only transiently required for regulating SVZ stem cell prolif-
eration in the early postnatal brain. However, the overall prolifer-
ation rate in Nf1hGFAPCKO SVZ was not significantly altered,Cell 150, 816–830, August 17, 2012 ª2012 Elsevier Inc. 823
Figure 5. Nf1 Inactivation Leads to Ectopic Expression of Olig2 in Neural Stem/Progenitor Cells in Neonatal Brains
(A) Sections from P0.5 control and Nf1hGFAPCKO brains were stained with H&E (a and a0) and Olig2 (b and b0).
(B) The percentage of Olig2+ cells in the SVZa was quantified.
(C and D) The proliferation rate of Olig2+ cells was not significantly different between the control and mutant SVZa. Arrows and arrowheads indicate Olig2+/Ki67+
and Olig2+/Ki67 cells, respectively.
(E and F) The percentage of Ascl1+ cells coexpressing Olig2 and/or Dlx2 in the control and mutant SVZa was analyzed and quantified. Arrows and arrowheads
indicate Olig2+/Dlx2+/Ascl1+ triple-positive cells and Olig2+/Dlx2/Ascl1+ double-positive cells, respectively.
(G and H) The expression of Olig2 and Dlx2 in the posterior control and mutant VZ/SVZ and IZ was analyzed and quantified.
Dashed lines demarcate the SVZa (A, C, and E) or VZ/SVZ regions from the IZ (G). All the quantification data are presented as mean ± SEM. LV and *, lateral
ventricle. Scale bars, 50 mm.
See also Figure S6.which was at least partially attributed to a slightly reduced prolif-
eration of Olig2+ cells (Figures 6O–6Q) (Lee et al., 2010). Most of
the differentiated Olig2+ cells, which were negative for Ki67
expression, accumulated in the anterior-dorsal parts of the
SVZ (Figure 6P, arrowheads), an area where an excessive
number of differentiated astrocytes were observed in the adult
Nf1hGFAPCKO SVZ (Figure 2A). Taken together, these results
demonstrate that ectopic expression of Olig2 in Ascl1+ progen-
itors caused by Nf1 inactivation manifests during neonatal824 Cell 150, 816–830, August 17, 2012 ª2012 Elsevier Inc.stages (Figure 6R), leading to increased gliogenesis in the
CC at the expense of neurogenesis in the OB. Consequently,
Nf1-related structural brain defects including enlarged CC and
reduced OB are both established during early postnatal stages.
Neonatal Erk Pathway Inhibition Rescues Structural
Brain Defects Caused by Nf1 Inactivation
To investigate the molecular mechanism underlying ectopic
Olig2 expression inNf1-deficient SVZ progenitors, we performed
a series of in vitro and in vivo experiments. We showed that
activation of Erk signaling pathway, but not phosphatidylinositol
3-kinase (PI3K)/Akt ormammalian target of rapamycin complex 1
(mTORC1), was associated with ectopic Olig2 expression in
Ascl1+ TAP/IPCs (Figures S8A–S8C; data not shown). In
paraffin-embedded brain sections, robust p-Erk staining was
only identified in a small number of SVZ cells in control neonatal
brains and was reduced to a minimal level in the control adult
SVZ (Figures S8A–S8B00), which is correlated with the diminished
gliogenic output in the adult SVZ. In contrast, p-Erk+ cells
were readily detected and greatly increased in both neonatal
and adult SVZ of Nf1hGFAPCKO brains (Figures S8A–S8B00).
Importantly, consistent with the finding that Nf1 inactivation
causes ectopic Olig2 expression specifically in Ascl1+ TAP/
IPCs, p-Erk expression was restricted to Ascl1+, Olig2+, and
someDlx2+ cells, but not GFAP+ cells in the SVZ of both neonatal
and adult Nf1hGFAPCKO brains (Figures S8A–S8D). Specifically,
over 80% and 90% of p-Erk+ cells in the adult Nf1hGFAPCKO
SVZ expressed Ascl1 and Olig2, respectively. These results
suggest that Nf1-mediated negative regulation of Erk signaling
may suppress Olig2 expression and, consequently, glial fates
in neurogenic Ascl1+ TAP/IPCs.
To test this model, we treated mice from P0.5 to P18
with a potent MEK/ERK pathway inhibitor (MEKi), PD0325901
(Sebolt-Leopold and Herrera, 2004). Despite being relatively
normal at birth, Nf1hGFAPCKO mice became hunched, scruffy,
and exhibited growth retardation within 1 week. Consequently,
Nf1hGFAPCKO mice can be readily identified from control litter-
mates from P8 on, and weighed only half as much as control
littermates by P18 (Figures 7A and 7B). Strikingly, this P0.5–
P18 treatment protocol completely rescued these phenotypes.
For example, the appearance of the MEKi-treated Nf1hGFAPCKO
mice was indistinguishable from control littermates at P18
(Figures 7A and 7B). The level of Erk activation in MEKi-treated
Nf1hGFAPCKO SVZ at P18 was reduced to the level of control
SVZ, and more importantly, the number of Olig2+ cells in the
mutant SVZ was rescued to the level of vehicle-treated controls
(Figures 7C–7C00). For the Ascl1+ progenitors, the percentage of
Olig2+ cells in MEKi-treated Nf1hGFAPCKO SVZ was also
reduced to control levels (Figure 7C00). In the CC, the density of
Olig2+ cells and GFAP+ cells in MEKi-treated Nf1hGFAPCKO
brains, albeit not completely rescued, was reduced to nearly
the levels of vehicle-treated controls (Figures 7D–7D00). Most
importantly, the enlarged CC phenotype was completely
rescued in the MEKi-treated Nf1hGFAPCKO brains (Figures 7D
and 7D0). Conversely, neuronal density and the size of the OB
were significantly increased in mutants after MEKi treatment,
particularly evidenced by the reappearance of neuronal clusters
that were only observed in the control OB (Figures 7E, E0, and
S8E–S8E00). These MEKi treatment experiments demonstrate
a potential therapeutic window for preventing and treating
NF1-associated structural brain defects.
DISCUSSION
Given the well-documented role of ERK activity in synaptic
transmission and memory formation, pharmacological interven-
tion of RAS/ERK signaling could provide an attractive thera-peutic strategy to ameliorate the substantial neurocognitive
burden associated with the NCFC syndromes (Davis and
Laroche, 2006; Samuels et al., 2009). However, it is unclear
to what degree development-related structural brain abnormal-
ities contribute to the cognitive deficits in NCFC syndrome
patients. Recent studies have revealed that the structural brain
abnormalities, particularly an enlarged CC, are identified in
a subpopulation of NF1 patients with severe learning disabilities
(Moore et al., 2000; Payne et al., 2010; Pride et al., 2010).
These observations provide strong support for the hypothesis
that these structural brain abnormalities could be responsible
for the severe forms of cognitive impairment observed in
a subset of NCFC patients. Thus, our study elucidates the
timing, and cellular and molecular mechanism(s), when and
by which hyperactive RAS/ERK signaling leads to the develop-
ment-related structural brain defects caused by biallelic Nf1
inactivation. More importantly, we demonstrate the neonatal
stage(s) as a critical therapeutic window for treating these brain
abnormalities.
Biallelic Inactivation as an NF1-Related Nontumor
Disease Mechanism
The mechanism underlying the extremely high level of variability
in disease manifestation among NF1 patients, even for those
with the same germline heterozygousmutations, is poorly under-
stood (Riccardi, 1992). Our study demonstrates that biallelic, but
not heterozygous, inactivation of Nf1 leads to structural brain
defects including enlarged CC. Moreover, our study shows
that biallelic inactivation of Nf1 in developing, but not adult,
neural stem cells results in an enlarged CC. The results are
consistent with the observations that (1) most glial cells in the
CC are generated by SVZ stem cells during perinatal stages,
and (2) only a minor population of the progeny derived from adult
SVZ stem cells contributes to glial cells in the CC (Marshall et al.,
2005; Richardson et al., 2006; Rowitch and Kriegstein, 2010).
Therefore, these observations suggest that the timing and
cellular target(s) of somatic ‘‘second-hit’’ events could pro-
foundly impact on the severity of disease manifestations, thus
providing a potential mechanism underlying high levels of
disease variability observed among NF1 patients. It has been
well established that benign and malignant tumors arising in
NF1 patients result from biallelic inactivation of NF1 (Cichowski
and Jacks, 2001). NF1/ tumor cells exhibit growth advantage,
leading to clonal expansion and thus clinically identifiable
diseases in NF1 patients. Similarly, because of the substantial
self-renewal capacities possessed by developing stem and
progenitor cell populations, a relatively small number of somatic
‘‘second-hit’’ events in these cells could produce a greater
number of NF1/ progeny, leading to more severe phenotypic
consequences than those with the ‘‘second-hit’’ events in
differentiated cells. It would be of particular interest to determine
whether somatic ‘‘second-hit’’ NF1 mutations indeed occur in
cells within the enlarged CC from human specimens, as previ-
ously demonstrated in other NF1-related nontumor lesions
including skin hyperpigmentation and bone abnormalities
(De Schepper et al., 2008; Stevenson et al., 2006). Alternatively,
a subset of NF1+/ cells could phenotypically behave like
NF1/ cells when they have aberrantly high activity of a recentlyCell 150, 816–830, August 17, 2012 ª2012 Elsevier Inc. 825
Figure 6. Reduced Neurogenesis Is Accompanied by Increased Gliogenesis in Nf1hGFAPCKO Brains during Neonatal SVZ Development
(A–C) The size of P0.5 (A) and P8 (B) control and mutant OB was measured and quantified from the dorsal view and the lateral view.
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identified ubiquitin-mediated NF1 degradation machinery (Tan
et al., 2011).
The Role of Nf1 in SVZ Stem and Progenitor Cells in the
Brain
During embryonic development, neurogenesis and gliogenesis
are temporally regulated and occur sequentially in the devel-
oping VZ and SVZ (Kriegstein and Alvarez-Buylla, 2009; Moly-
neaux et al., 2007). Recent studies using the same hGFAP-cre
driver show that Erk1 and Erk2 double-knockout mice exhibit
a significantly thinner VZ and SVZ and a reduction in the size
of the CC; likewise, Erk2 loss results in reduced proliferation of
SVZ TAP/IPCs during embryonic cortical development (Samuels
et al., 2008; Satoh et al., 2011). These mouse genetic studies
support the notion that ERK/Erk signaling pathway has an essen-
tial role in both human and mouse embryonic cortical develop-
ment. However, our study shows that Nf1 has a dispensable
role in embryonic cortical development. Specifically, the number
of deep- and upper-layer neurons aswell as laminar organization
of the cerebral cortex appear to be relatively normal in
Nf1hGFAPCKO brains. In the neonatal and adult SVZ, neurogene-
sis and gliogenesis occur simultaneously (Kriegstein and Al-
varez-Buylla, 2009). Our study indicates that the percentage of
Ascl1+ TAP/IPCs expressing Olig2 is highly correlated with the
glial output of neonatal and adult SVZ stem cell niches, 20%
and 9%, respectively. This observation is consistent with
previous studies showing that the regulation of Olig2 expression
in the Ascl1+ TAP/IPC compartment appears to be a critical
mechanism controlling the balance between gliogenesis and
neurogenesis in the postnatal SVZ stem cell niche (Cai et al.,
2007; Hack et al., 2005; Marshall et al., 2005; Menn et al.,
2006). Although Olig2 expression is activated by Sonic
hedgehog (Shh) signaling in developing ventral spinal cord and
forebrain, the signaling pathway(s) regulating Olig2 is relatively
less understood in the dorsal forebrain (Lagace et al., 2007; Lu
et al., 2000; Zhou et al., 2000). In cultured neural precursor cells,
fibroblast growth factor 2 (FGF2) promotes Olig2 expression in
an Erk-dependent but Shh-independent manner (Bilican et al.,
2008; Chandran et al., 2003; Kessaris et al., 2004). In light of
these in vitro studies, our study provides compelling in vivo
evidence supporting thatNf1-regulated Erk signaling plays a crit-
ical role in regulating Olig2 in both neonatal and adult SVZ cells.
Based on these observations, we propose that FGF-mediated
Ras/Erk signaling pathway induces Olig2 expression, triggering
the transition from neurogenesis to gliogenesis at the end of(D) The size of P18 control and Nf1hGFAPCKO OB was quantified.
(E–K) Control and Nf1hGFAPCKO mice were pulsed with BrdU at P8 and analyz
by BrdU/NeuN double labeling (arrows) in the granule cell layer (GCL) and per
was quantified. (H–K) The number of newly generated astrocytes (BrdU+/GFAP+)
(H and I, arrows) and quantified (J). Arrowheads label noncolocalizing cells. (K) Qu
population in the control and mutant CC.
(L and M) Proliferating GFAP+ cells are shown (arrows) and quantified in the con
(N and O) The quantification of total cells and the percentage of Ki67+ proliferati
(P and Q) Proliferating Olig2+ (Olig2+/Ki67+, arrows) and differentiated Olig2+/Ki67
Dashed lines demarcate the SVZ/RMS.
(R) Quantification and characterization of Ascl1+ cells in P8 SVZa based on their
All the quantification data are presented as mean ± SEM. *, lateral ventricle. Sca
See also Figure S7.cortical development. The critical role of Nf1 is to inhibit Ras/
Erk activity and, in turn, suppress Olig2 expression in a subset
of Ascl1+ TAP/IPCs, thereby ensuring persistent neurogenesis
in an otherwise gliogenic environment of the perinatal and adult
brain (Figure 7F). This model is supported by the observations
that hyperactive Erk signaling and ectopic Olig2 expression in
Nf1hGFAPCKO brains are almost exclusively observed in SVZ-C
Ascl1+ TAP/IPCs, but not in any other SVZ lineage cells. Thus,
our study demonstrates that the regulation of Erk signaling
pathway by Nf1 mainly occurs at the stages of SVZ TAP/IPC
cells. It is worth noting that Nf1 has functions that are critical
for glia and neurons in the other regions of the brain (Hegedus
et al., 2007; Lee et al., 2010; Zhu et al., 2005). Together, these
studies suggest that individual ERK pathway components
(e.g., NF1) may be rate limiting only in specific cell types and/
or during specific developmental stages, and this could
contribute to phenotypic heterogeneity among NCFC
syndromes.
Clinical Implication—A Therapeutic Window
of Opportunity
The most striking finding of this study is the robust therapeutic
response when an 18 day MEKi treatment protocol was deliv-
ered to neonatal Nf1hGFAPCKO mice, which suffer from struc-
tural brain defects (e.g., enlarged CC and reduced OB), weight
loss, and deteriorating health. Remarkably, this MEKi treatment
protocol not only rescues SVZ-associated glial versus neuronal
fate-specification defects and the size abnormalities observed
in the CC and OB but also dramatically improves the overall
health of Nf1hGFAPCKO mice (Figure 7A). These observations
suggest that Nf1-related brain pathologies are mainly caused
by hyperactivation of the Erk/MAPK signaling pathway, but
not other Ras-mediated signaling pathways (e.g., PI3K/Akt).
Furthermore, clinical studies indicate that optic nerve gliomas
only develop in younger children (<6 years) with NF1 and that
nearly half of plexiform neurofibromas are identified in children
younger than 5 years with NF1 (Listernick et al., 1999; Wagg-
oner et al., 2000). Taken together, we propose that this tran-
sient MEKi treatment protocol during early postnatal stages
might represent an exciting opportunity to prevent and treat
multiple NF1-associated tumor and nontumor manifestations
including structural brain defects, which are associated with
severe learning disabilities and are previously thought to be
‘‘irreversible’’ due to their hypothetical origin during embryonic
development.ed at P18. (E and F) SVZ-derived neurogenesis was analyzed and quantified
iglomerular layer (PGL) of the OB. (G) The density of NeuN+ cells in the OB
and oligodendrocytes (BrdU+/Olig2+) in the control and mutant CC is illustrated
antification of the proportion of GFAP+ versus Olig2+ cells in the total BrdU+ cell
trol and mutant SVZa at P8.
ng cells are shown for P8 control and mutant SVZ.
 (arrowheads) cells were shown and quantified in control andmutant P8 SVZa.
expression of Olig2 and/or Dlx2.
le bars, 1 mm (A and B) and 50 mm (E–P).
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Figure 7. Neonatal MEKi Treatment Rescues Brain Abnormalities Caused by Nf1 Inactivation
(A) Control and Nf1hGFAPCKO mice were treated with vehicle and MEKi from P0.5 to P18 and analyzed at P18.
(B) The body weight of treated control and mutant mice was quantified.
(C) Triple labeling of p-Erk/Olig2/Ascl1 was performed on brain sections of vehicle-treated control andNf1hGFAPCKO as well as MEKi-treatedNf1hGFAPCKOmice.
Arrows and arrowheads indicate Olig2+/Ascl1+ and Olig2+/Ascl1 cells, respectively. Of note, p-Erk+/Olig2+/Ascl1+ cells were only identified in vehicle-treated
mutants. (C0 and C00) The number of p-Erk+ cells and the percentage of Olig2+ cells among total SVZ Ascl1+ cells were quantified among vehicle andMEKi-treated
control and mutant mice.
828 Cell 150, 816–830, August 17, 2012 ª2012 Elsevier Inc.
EXPERIMENTAL PROCEDURES
Control and Mutant Mice
The control mice used in this study are a pool of phenotypically indistinguish-
able mice with genotypes of hGFAP-cre-;Nf1flox/flox, hGFAP-cre-;Nf1flox/+,
hGFAP-cre+;Nf1flox/+, and hGFAP-cre ±;Nf1KO/+. The mutant mice
(Nf1hGFAPCKO) used were of the genotypes hGFAP-cre+;Nf1flox/KO and
hGFAP-cre+;Nf1flox/flox. For inducible experiments, Nestin-creER+;Nf1flox/+
(TM+) mice were used as controls, whereas Nestin-creER+;Nf1flox/flox (TM+)
mice were used as mutants (Nf1NcreERCKO). Both inducible strains carry
R26LacZR allele as a reporter. Nf1hGFAPCKO and control mice were maintained
in the mixed backgrounds of C57Bl6, 129Svj, and FVB, which improve overall
health and life span of the mutant mice. Nestin-creER+;Nf1flox/flox and control
mice were maintained on the mixed C57Bl6 and 129Svj backgrounds. Age-
and littermate-matched control and mutant mice were used for analysis to
minimize the impact of modifier genes. All mice in this study were cared for ac-
cording to the guidelines that were approved by the Animal Care and Use
Committees of the University of Michigan at Ann Arbor.
MEK Inhibitor Treatment
MEK inhibitor (PD0325901; Sigma-Aldrich) was dissolved in DMSO at a
concentration of 25 mg/ml and resuspended in vehicle (0.5% hydroxypropyl
methyl-cellulose with 0.2% Tween 80; Sigma-Aldrich) at a concentration of
1 mg/ml. The solution was administered by oral gavage at the dosage of
5 mg/kg (body weight) daily to lactating females for the treatment of P0.5–
P18 mice. MEK inhibitor-treated mice were collected and compared to litter-
mate control and Nf1hGFAPCKO mice treated with vehicle.
Histological, Molecular, and Statistical Analyses
Detailed descriptions for the Experimental Procedures are provided in the
Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures
and eight figures and can be found with this article online at http://dx.doi.
org/10.1016/j.cell.2012.06.034.
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